| pubmed-article:2182099 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2182099 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2182099 | lifeskim:mentions | umls-concept:C0021734 | lld:lifeskim |
| pubmed-article:2182099 | lifeskim:mentions | umls-concept:C0024140 | lld:lifeskim |
| pubmed-article:2182099 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:2182099 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2182099 | pubmed:dateCreated | 1990-5-18 | lld:pubmed |
| pubmed-article:2182099 | pubmed:abstractText | Ten patients suffering from either discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) were treated with interferon alpha 2a. Eight received low or intermediate doses (18-45 x 10(6) U/week) for a short period of time (4-8 weeks), with marked improvement of skin lesions in six, an exacerbation in one patient and no change in the other. Two patients with SCLE received high doses (100-120 x 10(6) U/week) over 12 weeks, with complete clearing of the lesions in one and a marked improvement in the other. The responses were of short duration and within a few weeks of stopping treatment all who had improved or cleared relapsed. The side-effects in all the patients were fever and a flu-like syndrome which necessitated a reduction of the dose in one case. In two patients there were increases in the liver enzyme levels, but no haematological toxicity was noted. | lld:pubmed |
| pubmed-article:2182099 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2182099 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2182099 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2182099 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2182099 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2182099 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2182099 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2182099 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2182099 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:2182099 | pubmed:issn | 0007-0963 | lld:pubmed |
| pubmed-article:2182099 | pubmed:author | pubmed-author:NicolasJ FJF | lld:pubmed |
| pubmed-article:2182099 | pubmed:author | pubmed-author:ThivoletJJ | lld:pubmed |
| pubmed-article:2182099 | pubmed:author | pubmed-author:ChouvetBB | lld:pubmed |
| pubmed-article:2182099 | pubmed:author | pubmed-author:KanitakisJJ | lld:pubmed |
| pubmed-article:2182099 | pubmed:author | pubmed-author:LyonnetSS | lld:pubmed |
| pubmed-article:2182099 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2182099 | pubmed:volume | 122 | lld:pubmed |
| pubmed-article:2182099 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2182099 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2182099 | pubmed:pagination | 405-9 | lld:pubmed |
| pubmed-article:2182099 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:meshHeading | pubmed-meshheading:2182099-... | lld:pubmed |
| pubmed-article:2182099 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2182099 | pubmed:articleTitle | Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. | lld:pubmed |
| pubmed-article:2182099 | pubmed:affiliation | Clinique Dermatologique, Hôpital E. Herriot, Lyon, France. | lld:pubmed |
| pubmed-article:2182099 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2182099 | pubmed:publicationType | Clinical Trial | lld:pubmed |
